Form 4 for CLPT ClearPoint Neuro, Inc.
Accepted 2026-06-22 16:05:05 ET · period of report 2026-06-17 · accession 0001193125-26-277503 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-06-22 16:05 | 2026-06-17 | CLPT | BURNETT JOSEPH | CEO, Pres, Dir | M - OptEx | $2.50 | +60.0K | 176.8K | +51% | +$150.0K |
| DT | 2026-06-22 16:05 | 2026-06-17 | CLPT | BURNETT JOSEPH | CEO, Pres, Dir | S - Sale+OE | $17.79 | -60.0K | 116.8K | -34% | -$1.07M |
| DTI | 2026-06-22 16:05 | 2026-06-17 | CLPT | BURNETT JOSEPH | CEO, Pres, Dir | S - Sale+OE | $17.94 | -1,843 | 191.4K | -1.0% | -$33.1K |
| DT | 2026-06-22 16:05 | 2026-06-17 | CLPT | BURNETT JOSEPH | CEO, Pres, Dir | M - OptEx | $0.00 | -60.0K | 270.0K | -18% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-17 | M | A | 60,000 | $2.50 | 176,842 | D | — | — | (F1) The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 11, 2025 in accordance with Rule 10b5-1. |
| 2 | Common | Common Stock | 2026-06-17 | S | D | 60,000 | $17.79 | 116,842 | D | — | — | (F1) The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 11, 2025 in accordance with Rule 10b5-1. (F2) Represents a weighted average sales price per share. The shares were sold at prices ranging from $17.35 to $18.15. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 3 | Common | Common Stock | 2026-06-17 | S | D | 1,843 | $17.94 | 191,388 | I See Footnote | — | — | (F1) The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 11, 2025 in accordance with Rule 10b5-1. (F3) Represents a weighted average sales price per share. The shares were sold at prices ranging from $17.75 to $18.08. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. (F4) These shares are owned directly by the Joseph M. Burnett Trust dated 10/20/2022 and indirectly by Joseph M. Burnett as trustee of the trust. |
| 4 | Derivative | Stock Options (right to buy) | 2026-06-17 | M | D | 60,000 | $0.00 | 270,000 | D | $2.50 · — to 2027-11-07 | 60,000 Common Stock | (F1) The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 11, 2025 in accordance with Rule 10b5-1. (F5) The shares subject to this option vest as follows: (i) one-third of the total shares on the first anniversary of the grant date; and (ii) the remaining two-thirds of the total shares ratably on a quarterly basis over the 2-year period immediately following the first anniversary of the grant date. The grant date is November 7, 2017. |